Data as of Jan 23
| +0.26 / +4.28%|
The 11 analysts offering 12-month price forecasts for ImmunoGen Inc have a median target of 7.00, with a high estimate of 12.00 and a low estimate of 5.00. The median estimate represents a +10.58% increase from the last price of 6.33.
The current consensus among 14 polled investment analysts is to Hold stock in ImmunoGen Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.